Nebivololo Doc (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivololo Doc, is a beta blocker presented as an oral tablet for oral use. It is used to lower blood pressure and improve heart function in adults with hypertension or heart failure.

GNH USA supplies Nebivololo Doc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution. With a focus on regulatory compliance, GNH USA ensures product integrity throughout the supply chain, meeting the needs of diverse healthcare markets.

Nebivolol is indicated for cardiovascular conditions where reduction of blood pressure or improvement of cardiac output is required. - Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension. - Heart failure: improves left ventricular ejection fraction and reduces symptoms in chronic heart failure. - Left ventricular systolic dysfunction: enhances cardiac performance and may decrease hospitalization risk in patients with reduced ejection fraction.

Nebivolol may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate headache reported. - Dizziness: transient light‑headedness, especially on standing. - Fatigue: feeling of tiredness or reduced energy. - Nasal congestion: mild upper respiratory discomfort.

Serious or Rare Side Effects: - Severe bradycardia: heart rate markedly below normal requiring medical attention. - Symptomatic hypotension: sudden drop in blood pressure causing faintness or shock. - Bronchospasm: airway constriction in patients with reactive airway disease.

When prescribing nebivolol, clinicians should consider several precautionary measures to ensure safe use. - Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Heart rate assessment: monitor for bradycardia, especially in patients with conduction disorders. - Asthma or COPD caution: use carefully as β‑blockade may exacerbate bronchospasm. - Renal or hepatic impairment: dose adjustment may be required in moderate to severe dysfunction. - Concomitant antihypertensives: evaluate for additive blood pressure‑lowering effects. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other β‑blockers: additive bradycardia and hypotension. - Verapamil or diltiazem: increased risk of atrioventricular block. - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): elevated nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors or diuretics: enhanced antihypertensive effect, monitor blood pressure. - Insulin or sulfonylureas: may mask hypoglycemia symptoms, observe glucose levels. - Non‑selective β‑blockers: combined effect on heart rate and bronchial tone.